This text is a result of machine translation.
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Yesterday 12:13 PM
Research
Consumer StaplesChina’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
Qualcomm enters the game console market and promotes the development kit with thunder snake
China free: physical store sales returned to normal in September
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
In the second quarter, the public fund's heavy position stocks are released, and Guizhou Maotai is still the largest heavy position stocks